A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma
Phase of Trial: Phase II
Latest Information Update: 12 Jun 2017
At a glance
- Drugs SVN53-67-M57-KLH peptide vaccine (Primary) ; Montanide ISA-51; Sargramostim; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
- 12 Jun 2017 According to a MimiVax media release, interim data analysis from this trial has been completed.
- 06 Apr 2017 Planned End Date changed from 2 Apr 2018 to 2 Apr 2019.
- 06 Apr 2017 Planned primary completion date changed from 2 Apr 2017 to 2 Apr 2018.